Meningococcemia: Epidemiology, Pathophysiology, and Management

References 

1. American Academy of Pediatrics. AAP endorses new meningococcal vaccine guidelines. 2005;Retrieved June 8 2005, from http://www.aap.org/advocacy/releases/may05mv.htm.
2. American Academy of Pediatrics. Guillain-Barré cases among recipients of meningococcal conjugate vaccine: Interim guidance for physicians. 2005;Retrieved October, 14, 2005, from membership@listerv.aap.org.
3. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriquez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal of Medicine. 2001;344:699–709
4. Centers for Disease Control and Prevention. Meningococcal conjugate vaccine. 2005;Retrieved June 8 2005. from http://www.ckc.gov/nip/vaccine/mening/mcv4/mcv4_acip.htm.
5. Eli Lilly Corporation. (letter) Discontinuation of Study F1K-MC-EVBP, investigation of the efficacy and safety of drotrecogin alfa(activated) in pediatric severe sepsis. 2005;Retrieved October 12, 2005, from http://www.pedsccm.com.
6. Fischer M, Hilinski J, Stephens D. Adjuvant therapy for meningococcal sepsis. The Pediatric Infectious Disease Journal. 2005;24:177–178
   • MEDLINE
   • CrossRef
7. Healy CM, Baker CJ. The future of meningococcal vaccines. The Pediatric Infectious Disease Journal. 2005;24:175–176
   • MEDLINE
   • CrossRef
8. Kirsch EA, Barton RP, Kitchen L, Giroir BP. Pathophysiology, treatment and outcome of meningococcemia: A review and recent experience. The Pediatric Infectious Disease Journal. 1996;15:967–979
   • MEDLINE
   • CrossRef
9. Levin M, Quint PA, Goldstein B, Barton P, Bradley JS, Shemie SD, et al. Recombinant bactericidal/ permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: A randomized trial. Lancet. 2000;356:961–967
   • Abstract
   • Full Text
   • Full-Text PDF (107 KB)
   • CrossRef
10. McIntyre PB, Berkey C, King SM, Schaad UB, Kilpi T, Kanra GY, et al. Dexamethasone as adjunctive therapy in bacterial meningitis: A meta-analysis of randomized clinical trials since 1988. JAMA. 1997;278:9925–9931
11. Pathan N, Faust SN, Levin M. Pathophysiology of meningococcal meningitis and septicaemia. Archives of Diseases in Childhood. 2003;88:601–607
    • CrossRef
12. Pichichero M, Casey J, Blatter M, Rothestein E, Ryall R, Bybel M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A,C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two-to ten-year-old children. Pediatric Infectious Disease Journal. 2005;24:57–62
13. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes J. Medical progress: Meningococcal disease. New England Journal of Medicine. 2001;344:1378–1388
14. Welch SB, Nadel S. Treatment of meningococcal infection. Arch Dis Child. 2003;88:608–614
    • CrossRef
15. World Health Organization. Meningococcal meningitis (Fact Sheet). 2003;Retrieved June 7, 2005, from http://www.who.int/mediacentre/factsheets/fs141/en/print.html.
16. Zaritsky AL, Nadkarni VM, Hickey RW, Schexnayder S, Berg RA. Pediatric Advanced Life Support provider manual. Dallas, TX: American Heart Association; 2002;